Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia: An interrupted time-series analysis

Hum Vaccin Immunother. 2018 May 4;14(5):1230-1233. doi: 10.1080/21645515.2018.1425115. Epub 2018 Feb 12.

Abstract

Colombia introduced mass pneumococcal conjugate vaccination at the end of 2011. Using 2005-2015 surveillance data, we conducted a retrospective interrupted time-series analysis. A significant trend towards reduced monthly was observed in the post-vaccination period (2012-2015) compared with the expected rate, reaching in 2015 a reduction of 90.5% of pneumococcal meningitis. This trend was not observed for control diseases.

Keywords: Colombia; Pneumococcal conjugate vaccine; meningitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colombia / epidemiology
  • Epidemiological Monitoring*
  • Humans
  • Incidence
  • Mass Vaccination / methods*
  • Mass Vaccination / standards
  • Meningitis, Pneumococcal / epidemiology*
  • Meningitis, Pneumococcal / immunology
  • Meningitis, Pneumococcal / microbiology
  • Meningitis, Pneumococcal / prevention & control
  • Pneumococcal Vaccines / therapeutic use*
  • Retrospective Studies
  • Streptococcus pneumoniae / immunology*
  • Streptococcus pneumoniae / isolation & purification
  • Vaccines, Conjugate / therapeutic use

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate

Grants and funding

GlaxoSmithKline Biologicals SA (Rixensart, Belgium) was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA (Rixensart, Belgium) also took in charge all costs associated with the development and the publishing of the present manuscript. All authors had full access to the data and the corresponding author had final responsibility to submit the manuscript for publication.